D A Dornbierer, M Boxler, C D Voegel, B Stucky, A E Steuer, T M Binz, M R Baumgartner, D M Baur, B B Quednow, T Kraemer, E Seifritz, H P Landolt, O G Bosch
BACKGROUND: Gamma-hydroxybutyrate (GHB; or sodium oxybate) is an endogenous GHB-/gamma-aminobutyric acid B receptor agonist. It is approved for application in narcolepsy and has been proposed for the potential treatment of Alzheimer's disease, Parkinson's disease, fibromyalgia, and depression, all of which involve neuro-immunological processes. Tryptophan catabolites (TRYCATs), the cortisol-awakening response (CAR), and brain-derived neurotrophic factor (BDNF) have been suggested as peripheral biomarkers of neuropsychiatric disorders...
October 1, 2019: International Journal of Neuropsychopharmacology